Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by BROCKER, P.
Right arrow Articles by POYNARD, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BROCKER, P.
Right arrow Articles by POYNARD, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 Oxford University Press

research-article

A Two-centre, Randomized, Double-blind Trial of Ornithine Oxoglutarate in 194 Elderly, Ambulatory, Convalescent Subjects

PATRICE BROCKER, BRUNO VELLAS, JEAN-LOUIS ALBAREDE and THIERRY POYNARD

CHU Nice, Hôpital de Cantaron 254 Chemin de la Lauvette, 0634 La Trinité, France
Centre de Medecine Gériatrique, CPU Purpan Toulouse
Service d'Hépato-Gastroentérologie, CHU Antoine Béclère Clamart

In a double-blind trial, 194 ambulatory elderly patients (mean age, 74±8 years) recovering from acute illnesses were randomly assigned to receive either ornithine oxoglutarate (OGO) or a placebo. Nine subjects withdrew during the study, six in the OGO group and three in the placebo group.

OGO and the placebo were administered once daily at a dose of 10 g after lunch for 2 months; the patients were monitored for a total of 4 months. Efficacy was evaluated in terms of nutritional variables, quality of life and total cost of medical treatment.

The analysis involved a total of 185 patients (93 in the placebo group and 92 in the OGO group). The two groups were comparable at inclusion. After 30 and 60 days of treatment, there was a significant improvement in the following variables in the OGO group relative to the placebo group: appetite (p<0.001), body weight (p<0.001) and independence (p<0.01). Two months after the end of treatment, there was still a significant improvement in the quality-of-life index (p<0.001) and the medical-cost index (p<0.03) in the OGO group, with an overall cost saving of 37%. We conclude that OGO seems to be a cost-effective nutritional supplement for elderly convalescent patients.

Received December 7, 1993;
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JPEN J Parenter Enteral NutrHome page
C. Pritchard, S. Duffy, J. Edington, and F. Pang
Enteral Nutrition and Oral Nutrition Supplements: A Review of the Economics Literature
JPEN J Parenter Enteral Nutr, January 1, 2006; 30(1): 52 - 59.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
S. M.H. Alibhai, C. Greenwood, and H. Payette
An approach to the management of unintentional weight loss in elderly people
Can. Med. Assoc. J., March 15, 2005; 172(6): 773 - 780.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
S.-S. Yeh and M. W Schuster
Geriatric cachexia: the role of cytokines
Am. J. Clinical Nutrition, August 1, 1999; 70(2): 183 - 197.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.